Bioray Laboratories

This study follows people who have already received an experimental gene therapy called BRL-101 for transfusion-dependent β-thalassemia, a severe blood disorder requiring regular transfusions. Researchers will monitor participants over the long term to check for safety issues, su…

This early study tests a new treatment called BCMA-UCART for adults with multiple myeloma that has come back or stopped responding to other therapies. The treatment uses donor immune cells that are specially designed to find and attack cancer cells. The main goals are to see if t…

This early-stage study tests a new treatment called BRL-201 for people with relapsed or refractory B-cell non-Hodgkin lymphoma. The therapy uses a patient's own immune cells, modified to target cancer cells, and aims to control the disease. About 12-18 adults will participate to …

This early study tests a one-time treatment using universal (off-the-shelf) CAR-T cells that target CD19, a protein on cancer cells. It is for adults with relapsed or refractory B-cell non-Hodgkin lymphoma who have few options left. The main goal is to check safety and find the r…